Sintilimab plus chemo before and after surgery for advanced oral cancer
Part of Cancer clinical trials.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of mouth cancer called oral squamous cell carcinoma that is stage III or IVA and has not spread too far.
- You are willing and able to have surgery to remove the cancer.
- You have good overall health, including adequate blood counts, kidney and liver function, and no serious heart or lung problems.
- You have not had previous treatment with certain immunotherapy drugs or radiation to the head or neck area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (sintilimab) together with chemotherapy before surgery can help treat oral cavity cancer. The goal is to shrink the tumor and possibly improve outcomes for patients with early-stage cancer that hasn't spread.
This trial tests whether adding a type of radiation therapy (SBRT) to chemoimmunotherapy before surgery helps people with advanced mouth or throat cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) and two standard chemotherapy drugs (carboplatin and albumin-bound paclitaxel) before surgery for advanced oral cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
This trial is testing a combination of low-dose radiation, immunotherapy, and chemotherapy for people with advanced oral cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer and possibly improve outcomes.
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
Hear when a new Locally Advanced Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.